PMID- 33634250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 2574-0954 (Electronic)
IS  - 2574-0954 (Linking)
VI  - 10
IP  - 1
DP  - 2021 Mar
TI  - Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights 
      into preservation of sight and looking beyond.
PG  - 3-13
LID - 10.1097/XCE.0000000000000209 [doi]
AB  - Sodium-glucose co-transporter 2 Inhibitors (SGLT2i) were initially developed as 
      therapeutic options for patients with type 2 diabetes mellitus (T2DM). Recently, 
      randomized clinical trials have investigated their effects in cardiorenal 
      protection through major adverse cardiovascular event reduction and reductions in 
      diabetic nephropathy. While multiple mechanisms are proposed for this protection, 
      microvascular protection is the primary component of their efficacy. While not 
      primarily emphasized in clinical trials, evidence in other studies suggests that 
      SGLT2i may confer retinoprotective effects via some of the same mechanisms in the 
      aforementioned cardiorenal trials. Diabetic patients are susceptible to vision 
      loss with chronic hyperglycemia promoting inflammation, edema, and retinal 
      pathological changes. Targeting these pathways via SGLT2i may represent 
      opportunities for providers to decrease retinopathy in high-risk T2DM patients, 
      reduce disease progression, and lower drug burden in diabetic retinopathy 
      patients. Further comprehensive clinical trials investigating these associations 
      are needed to establish the potential retinoprotective effects of SGLT2i.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Lahoti, Sejal
AU  - Lahoti S
AD  - Department of Ophthalmology, Long School of Medicine, University of Texas Health 
      San Antonio.
FAU - Nashawi, Mouhamed
AU  - Nashawi M
AD  - Division of Medicine-Cardiology, University of Texas Health Science Center San 
      Antonio, San Antonio, Texas, USA.
FAU - Sheikh, Omar
AU  - Sheikh O
AD  - Division of Medicine-Cardiology, University of Texas Health Science Center San 
      Antonio, San Antonio, Texas, USA.
FAU - Massop, David
AU  - Massop D
AD  - Department of Ophthalmology, Long School of Medicine, University of Texas Health 
      San Antonio.
FAU - Mir, Mahnoor
AU  - Mir M
AD  - Division of Medicine-Cardiology, University of Texas Health Science Center San 
      Antonio, San Antonio, Texas, USA.
FAU - Chilton, Robert
AU  - Chilton R
AD  - Division of Medicine-Cardiology, University of Texas Health Science Center San 
      Antonio, San Antonio, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200518
PL  - United States
TA  - Cardiovasc Endocrinol Metab
JT  - Cardiovascular endocrinology & metabolism
JID - 101730894
PMC - PMC7901818
OTO - NOTNLM
OT  - diabetes
OT  - diabetic
OT  - diabetology
OT  - microvascular
OT  - ophthalmology
OT  - retina
OT  - retinopathy
OT  - sodium-glucose co-transporter 2 inhibitors
OT  - translational biology
OT  - vision loss
EDAT- 2021/02/27 06:00
MHDA- 2021/02/27 06:01
PMCR- 2020/05/18
CRDT- 2021/02/26 06:05
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2021/02/26 06:05 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/02/27 06:01 [medline]
PHST- 2020/05/18 00:00 [pmc-release]
AID - 10.1097/XCE.0000000000000209 [doi]
PST - epublish
SO  - Cardiovasc Endocrinol Metab. 2020 May 18;10(1):3-13. doi: 
      10.1097/XCE.0000000000000209. eCollection 2021 Mar.